Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 28, 2019Clinical Cancer ResearchOpen Access

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLaura MorenoCPCristina PérezAZAintzane Zabaleta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Moreno et al. (2019) studied this question.

synapsesocial.com/papers/6a0cf4194e02b7512ccc8e2chttps://doi.org/10.1158/1078-0432.ccr-18-1597
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide2014 · 109 citations
  2. 2Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab2010 · 217 citations
  3. 3Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients2016 · 151 citations
  4. 4Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma2015 · 1,135 citations
  5. 5Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells2010 · 257 citations